# Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea

Study · id `cardio:ct-nct06690723` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06690723](<https://clinicaltrials.gov/study/NCT06690723>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06690723

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT06690723. Randomized; single masking; primary purpose treatment. Start 2022-06-08 (actual); primary completion 2024-09-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT06690723, source copy `cardio:ctgov-nct06690723-2024-11-15`, retrieved 2026-10-26)
- Started: 2022-06-08 (actual) (ClinicalTrials.gov record NCT06690723, source copy `cardio:ctgov-nct06690723-2024-11-15`, retrieved 2026-10-26)
- Primary completion: 2024-09-03 (actual) (ClinicalTrials.gov record NCT06690723, source copy `cardio:ctgov-nct06690723-2024-11-15`, retrieved 2026-10-26)
- Completion: 2024-09-03 (actual) (ClinicalTrials.gov record NCT06690723, source copy `cardio:ctgov-nct06690723-2024-11-15`, retrieved 2026-10-26)
- Countries: Malaysia (ClinicalTrials.gov record NCT06690723, source copy `cardio:ctgov-nct06690723-2024-11-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06690723-2024-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea
- Acronym: D3DOSA
- Condition: Obstructive Sleep Apnea
- Intervention (Drug): Dapagliflozin (Forxiga)
- Intervention (Drug): Vitamin D3 ( Colecalciferol)
- Intervention (Drug): Vitamin D3 plus Dapagliflozin
- Intervention (Behavioral): Lifestyle modification
- Lead sponsor: University Malaysia Sarawak
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients (`cardio:pubmed-40055713`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2b4c40748e821a202c512f000fc2c84389c2e54ef88dad6fd60258e03bd4a7c9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
